Oncologic outcomes among patients undergoing fertility-sparing treatment of atypical hyperplasia and grade one cancer of the endometrium using progestin therapy: Results of a novel, specialized, oncofertility program.

MLA

Dzyubak, Oleksandra, et al. “Oncologic Outcomes among Patients Undergoing Fertility-Sparing Treatment of Atypical Hyperplasia and Grade One Cancer of the Endometrium Using Progestin Therapy: Results of a Novel, Specialized, Oncofertility Program.” Gynecologic Oncology, vol. 190, Nov. 2024, pp. S373–74. EBSCOhost, https://doi.org/10.1016/j.ygyno.2024.07.555.

APA

Dzyubak, O., Kim, R. S., Glass, K., Watts, M., Tarafdar, O., Simpson, A., Maganti, M., Deljoomanesh, S., Laframboise, S., & Ferguson, S. (2024). Oncologic outcomes among patients undergoing fertility-sparing treatment of atypical hyperplasia and grade one cancer of the endometrium using progestin therapy: Results of a novel, specialized, oncofertility program. Gynecologic Oncology, 190, S373–S374. https://doi.org/10.1016/j.ygyno.2024.07.555

Chicago

Dzyubak, Oleksandra, Rachel Soyoun Kim, Karen Glass, Megan Watts, Oishika Tarafdar, Andrea Simpson, Manjula Maganti, Shima Deljoomanesh, Stephane Laframboise, and Sarah Ferguson. 2024. “Oncologic Outcomes among Patients Undergoing Fertility-Sparing Treatment of Atypical Hyperplasia and Grade One Cancer of the Endometrium Using Progestin Therapy: Results of a Novel, Specialized, Oncofertility Program.” Gynecologic Oncology 190 (November): S373–74. doi:10.1016/j.ygyno.2024.07.555.